多发性骨髓瘤的CAR-T细胞治疗:现状与前景
该综述指出BCMA是CAR-T治疗多发性骨髓瘤的理想靶点,多项试验显示抗BCMA CAR-T在重度预处理患者中诱导高质量缓解包括MRD阴性。目前III期试验正在早期阶段患者中比较CAR-T与标准方案,但多数患者最终复发,与CAR-T细胞丢失、抗原丢失或免疫抑制微环境相关。
要点
- BCMA仅表达于正常和恶性浆细胞及部分成熟B细胞,是CAR-T理想靶点。
- 抗BCMA CAR-T在重度预处理骨髓瘤患者中诱导高质量缓解包括MRD阴性。
- 毒性包括细胞因子释放综合征、各类血细胞减少、感染和神经毒性。
核心结论
- 抗BCMA CAR-T在多发性骨髓瘤中显示高质量缓解,但多数患者最终复发。
研究设计与样本
- 综述类文章,检索范围未明确报告。
主要发现
- 多项抗BCMA CAR-T试验在重度预处理骨髓瘤患者中显示高质量缓解包括MRD阴性。
- 部分患者持续缓解超过1年,但多数最终复发。
- 复发可能与CAR-T细胞丢失、肿瘤细胞表面抗原表达丢失或免疫抑制微环境损害T细胞活性相关。
关键数值与推荐
- BCMA(TNFRSF17)仅由正常和恶性浆细胞及部分成熟B细胞表达。
- CAR融合蛋白包含抗原识别域、T细胞激活域(如CD3ζ [CD247])和共刺激域(如CD28或4-1BB [TNFRSF9, 又称CD137])。
临床怎么用
- III期试验正在早期阶段患者中评估CAR-T对比标准治疗方案。
- 新诊断高危细胞遗传学或移植后残留病患者正在开展CAR-T试验。
- 靶向CD19、CD38、CD138(SYND1)和SLAMF7等其他抗原的CAR-T也在探索中。
局限性
- 多数患者最终复发,与CAR-T细胞丢失、抗原丢失或免疫抑制微环境相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory domain (eg, CD28 or 4-1BB [TNFRSF9, also known as CD137]). The B-cell maturation antigen (BCMA; TNFRSF17) is an attractive target for CAR T-cell therapy because it is only expressed by normal and malignant plasma cells and by a subset of mature B cells. Several trials of anti-BCMA CAR T cells have shown high-quality responses, including minimal residual disease-negativity in patients with multiple myeloma who were heavily pretreated. Phase 3 trials are currently evaluating CAR T-cell therapy versus standard-of-care regimens in patients in earlier stages of the disease. Trials are also ongoing in newly diagnosed patients with high-risk cytogenetic profiles or with residual disease after transplantation. CAR T cells targeting other multiple myeloma antigens, such as CD19, CD38, CD138 (SYND1), and SLAMF7, are also being explored. Toxicities associated with CAR T cells include cytokine-release syndrome, different types of cytopenia, infections, and neurotoxicity. Although some subsets of patients have sustained responses for more than 1 year, most patients eventually relapse, which might be related to the loss of CAR T cells, loss of antigen expression on the tumour cell surface, or to an immunosuppressive microenvironment that impairs the activity of T cells. Efforts to improve the effectiveness of CAR T-cell therapy include optimising CAR design and adapting the manufacturing process to generate cell products enriched for specific subsets of T cells (eg, early memory cells). Other strategies explored in trials include dual-antigen targeting to prevent antigen escape and rational combination therapy to enhance persistence. Several approaches are also being developed to improve the safety of CAR T-cell therapy, such as the incorporation of a suicide gene safety system.
引用
- van de Donk NWCJ, Usmani SZ, Yong K, et al. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021. PMID: 34048683. doi:10.1016/S2352-3026(21)00057-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。